Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

30 Nov 2005 07:04

Original Investments PLC30 November 2005 Original Investments PLC ("Original Investments" or "the Company") Acrobot update An innovative medical device, enabling orthopaedic surgeons to accurately planand perform hip resurfacing surgery, has been granted a CE-mark by BSI'sCertification Panel. The surgical navigation product has been developed by TheAcrobot Company ("Acrobot") in which Original Investments, the AIM-quotedinvestment company, has a 25% shareholding. The device has been developed incollaboration with Corin Group PLC ("Corin"), and the CE-mark is themanufacturer's guarantee that the device meets all the required Europeanmanufacturing and safety standards. Acrobot develops surgical systems for minimally-invasive, bone-conservingorthopaedic surgery. The new device, called Acrobot(R) Navigation, is beingcommercialised by Corin, under the name of Wayfinder(R), to enable accurateimplantation of the company's metal on metal hip resurfacing implant.Clinical trials are to start immediately at a London hospital. Justin Cobb,Professor of Orthopaedics at Imperial College, will lead the alpha site. Twoadditional sites in the UK and a third in Australia will start evaluation of theAcrobot(R) Navigation system in the second quarter of 2006. The device will bein wider use from the second half of 2006. The Acrobot(R) Navigation system gives the surgeon the ability to accuratelyimplant hip resurfacing prostheses in a minimally invasive procedure. It differsfrom competitive products by using mechanical tracking rather than optical orelectromagnetic technologies, giving it a higher accuracy at a lower cost.Acrobot believes that this unique selling point will increase the use of thetechnology, making it accessible to a larger number of surgeons and patients.The Acrobot(R) Navigation system has been developed by the Acrobot team at thecompany's laboratories in London. Acrobot is seeking licensees and distributorsfor applications of Navigation to other orthopaedic procedures. It is the secondof a number of related products to be produced by Acrobot, having launched theAcrobot(R) Planner software and service last month. A third product planned forlaunch in 2006 is the Acrobot(R) Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. Enquiries to: Dr. Paula Gomes, Director of OperationsThe Acrobot Company Ltd, Tel: +44 (0)20 7403 5866, Email:enquiries@acrobot.co.ukor Terry Bond, Managing Director, Original Investments PLC 44 (0) 1235 834734.Email: tb@originalinvestments.com About The Acrobot Company Ltd The Acrobot Company Ltd develops precision surgical systems for minimallyinvasive, bone conserving, orthopaedic surgery. The Company was founded sixyears ago by Imperial Innovations as a collaboration to combine the skills ofclinicians and academics Using proprietary surgical planning software andstate-of-the-art Hands-On Robotics(TM), and Passive Constraint Navigation(TM)systems, Acrobot's products assist surgeons in achieving better patient outcomesby improving surgical precision and reducing surgical errors, while loweringoverall procedure cost. About Original Investments PLC Original Investments PLC, formerly called BioProjects International PLC, isquoted on the AIM market of the London Stock Exchange. The Company specializesin providing finance for early-stage companies that can demonstrate immediategrowth prospects and significant financial potential. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.